MX361600B - Identificación de anticuerpos humanos con maduración de afinidad. - Google Patents

Identificación de anticuerpos humanos con maduración de afinidad.

Info

Publication number
MX361600B
MX361600B MX2014000431A MX2014000431A MX361600B MX 361600 B MX361600 B MX 361600B MX 2014000431 A MX2014000431 A MX 2014000431A MX 2014000431 A MX2014000431 A MX 2014000431A MX 361600 B MX361600 B MX 361600B
Authority
MX
Mexico
Prior art keywords
primers
region
nucleic acids
amplified
sequence
Prior art date
Application number
MX2014000431A
Other languages
English (en)
Spanish (es)
Other versions
MX2014000431A (es
Inventor
Simard John
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2014000431A publication Critical patent/MX2014000431A/es
Publication of MX361600B publication Critical patent/MX361600B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2014000431A 2011-07-12 2012-07-12 Identificación de anticuerpos humanos con maduración de afinidad. MX361600B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506749P 2011-07-12 2011-07-12
PCT/US2012/046431 WO2013009967A2 (en) 2011-07-12 2012-07-12 Identifying affinity-matured human antibodies

Publications (2)

Publication Number Publication Date
MX2014000431A MX2014000431A (es) 2014-09-04
MX361600B true MX361600B (es) 2018-12-11

Family

ID=47506915

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000431A MX361600B (es) 2011-07-12 2012-07-12 Identificación de anticuerpos humanos con maduración de afinidad.
MX2018015450A MX2018015450A (es) 2011-07-12 2014-01-10 Identificacion de anticuerpos humanos con maduracion de afinidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018015450A MX2018015450A (es) 2011-07-12 2014-01-10 Identificacion de anticuerpos humanos con maduracion de afinidad.

Country Status (11)

Country Link
US (6) US9234030B2 (https=)
EP (2) EP2731965A4 (https=)
JP (1) JP6731702B2 (https=)
KR (1) KR102139388B1 (https=)
CN (2) CN107090459A (https=)
AU (2) AU2012281078B2 (https=)
CA (1) CA2841475C (https=)
IL (2) IL230358B (https=)
MX (2) MX361600B (https=)
RU (2) RU2762685C2 (https=)
WO (1) WO2013009967A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6731702B2 (ja) * 2011-07-12 2020-07-29 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 親和性成熟化ヒト抗体の同定
US10119134B2 (en) 2013-03-15 2018-11-06 Abvitro Llc Single cell bar-coding for antibody discovery
GB201316644D0 (en) * 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
WO2015182749A1 (ja) * 2014-05-30 2015-12-03 国立大学法人富山大学 TCR cDNAの増幅方法
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
ES2895750T3 (es) 2014-09-15 2022-02-22 Abvitro Llc Secuenciación de alto rendimiento de colecciones de nucleótidos
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US20200392578A1 (en) * 2019-06-14 2020-12-17 The Regents Of The University Of California Methods of sequencing antibody chains from hybridomas and kits for practicing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284897T1 (de) * 2000-03-10 2005-01-15 Large Scale Biology Corp Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
AU2002953381A0 (en) * 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
BRPI0412217A (pt) * 2003-07-29 2006-08-22 Genentech Inc método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP5205597B2 (ja) * 2007-06-01 2013-06-05 静岡県 1細胞レベルでの抗体遺伝子の解析・同定方法
RU2011117213A (ru) * 2008-09-30 2012-11-10 Эббот Лэборетриз (Us) Улучшенные библиотеки антител
EP2398913B1 (en) 2009-02-20 2016-03-30 F. Hoffmann-La Roche AG Method for obtaining immunoglobulin encoding nucleic acid
JP6731702B2 (ja) * 2011-07-12 2020-07-29 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 親和性成熟化ヒト抗体の同定

Also Published As

Publication number Publication date
US9394536B2 (en) 2016-07-19
IL262977A (en) 2018-12-31
EP3034513A2 (en) 2016-06-22
KR20140044905A (ko) 2014-04-15
IL230358B (en) 2018-11-29
US9453217B2 (en) 2016-09-27
JP6731702B2 (ja) 2020-07-29
MX2014000431A (es) 2014-09-04
US20200071388A1 (en) 2020-03-05
KR102139388B1 (ko) 2020-07-30
EP2731965A2 (en) 2014-05-21
EP3034513A3 (en) 2016-08-10
US20130018173A1 (en) 2013-01-17
WO2013009967A2 (en) 2013-01-17
EP2731965A4 (en) 2015-06-03
JP2014521316A (ja) 2014-08-28
WO2013009967A3 (en) 2013-04-04
CN103687873B (zh) 2016-10-19
EP3034513B1 (en) 2020-09-02
AU2017210585B2 (en) 2019-07-25
AU2012281078B2 (en) 2017-05-04
CA2841475C (en) 2021-02-09
AU2012281078A1 (en) 2014-01-23
RU2017134418A3 (https=) 2021-06-10
US9670483B2 (en) 2017-06-06
US9234030B2 (en) 2016-01-12
MX2018015450A (es) 2021-11-16
RU2017134418A (ru) 2019-02-07
RU2014102617A (ru) 2015-08-20
CN103687873A (zh) 2014-03-26
US20160060618A1 (en) 2016-03-03
AU2017210585A1 (en) 2017-08-24
CN107090459A (zh) 2017-08-25
US20160060619A1 (en) 2016-03-03
CA2841475A1 (en) 2013-01-17
US20170233457A1 (en) 2017-08-17
IL262977B (en) 2020-07-30
RU2636045C2 (ru) 2017-11-17
RU2762685C2 (ru) 2021-12-22
US20160362679A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
MX2018015450A (es) Identificacion de anticuerpos humanos con maduracion de afinidad.
Karlikow et al. CRISPR-induced DNA reorganization for multiplexed nucleic acid detection
Brind’Amour et al. An ultra-low-input native ChIP-seq protocol for genome-wide profiling of rare cell populations
He et al. Cas3 protein—a review of a multi-tasking machine
MY204975A (en) Complex surface-bound transposome complexes
Benz et al. Type IV-A3 CRISPR-Cas systems drive inter-plasmid conflicts by acquiring spacers in trans
BR112020006757A2 (pt) diagnóstico baseado no sistema de efetor crispr
CN112020562A (zh) 基于crispr效应系统的诊断
SA523441205B1 (ar) التحرير المتعدد للجينوم
WO2015160895A3 (en) Modified transposases for improved insertion sequence bias and increased dna input tolerance
AU2009355009A8 (en) THD primer target detection
WO2009045344A3 (en) Error-free amplification of dna for clonal sequencing
NZ781020A (en) Humanized universal light chain mice
JP2014521316A5 (https=)
Xu et al. Gene activation by a CRISPR-assisted trans enhancer
Blanch-Asensio et al. In vitro assembly of plasmid DNA for direct cloning in Lactiplantibacillus plantarum WCSF1
Yeom et al. Cell-free bacteriophage genome synthesis using low-cost sequence-verified array-synthesized oligonucleotides
SG11201809242VA (en) Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
Kinimi et al. Complete genome sequencing of field isolates of Peste des petits ruminants virus from Tanzania revealed a high nucleotide identity with lineage III PPR viruses
Zhao et al. Achieving optimal transfection conditions in chicken primordial germ cells under feeder-and serum-free medium
US20220259605A1 (en) Modified cell
Alessi et al. A rapid, sensitive, low-cost assay for detecting hydrogenotrophic methanogens in anaerobic digesters using loop-mediated isothermal amplification
Liu et al. High-throughput reformatting of phage-displayed antibody fragments to IgGs by one-step emulsion PCR
DK2399928T3 (da) Specifikke TT-virus-sekvenser og kimæriske TT-virusværtscelle-DNA-molekyler til anvendelse ved diagnosticering, forebyggelse og behandling af cancer og auto-immunitet
US20210381001A1 (en) A method to treat disease using a nucleic acid vector encoding a highly compact multi-input logic gate

Legal Events

Date Code Title Description
FG Grant or registration